| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 80 | 2022 | 364 | 10.890 |
Why?
|
| Stroke | 91 | 2022 | 2162 | 7.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 39 | 2021 | 99 | 5.520 |
Why?
|
| Sleep Apnea, Obstructive | 7 | 2017 | 142 | 3.260 |
Why?
|
| Blood Transfusion | 24 | 2020 | 205 | 2.830 |
Why?
|
| Stroke Rehabilitation | 7 | 2022 | 335 | 2.420 |
Why?
|
| Brain Ischemia | 18 | 2019 | 665 | 2.100 |
Why?
|
| Cerebrovascular Disorders | 23 | 2021 | 182 | 1.940 |
Why?
|
| Risk Factors | 62 | 2020 | 5720 | 1.800 |
Why?
|
| Humans | 215 | 2022 | 68549 | 1.700 |
Why?
|
| Adolescent | 82 | 2022 | 8904 | 1.640 |
Why?
|
| Child | 81 | 2022 | 6401 | 1.600 |
Why?
|
| Child, Preschool | 61 | 2022 | 3187 | 1.580 |
Why?
|
| Male | 141 | 2022 | 37283 | 1.500 |
Why?
|
| Life Style | 9 | 2019 | 338 | 1.500 |
Why?
|
| South Australia | 18 | 2019 | 19 | 1.420 |
Why?
|
| Asthma | 12 | 2009 | 345 | 1.410 |
Why?
|
| Australia | 19 | 2020 | 235 | 1.410 |
Why?
|
| Telemedicine | 11 | 2017 | 699 | 1.400 |
Why?
|
| Cerebrovascular Circulation | 21 | 2021 | 296 | 1.380 |
Why?
|
| Health Status Disparities | 5 | 2018 | 326 | 1.380 |
Why?
|
| Aged | 62 | 2022 | 14842 | 1.290 |
Why?
|
| Middle Aged | 75 | 2022 | 21119 | 1.280 |
Why?
|
| Female | 131 | 2022 | 38021 | 1.270 |
Why?
|
| Tissue Plasminogen Activator | 9 | 2017 | 296 | 1.240 |
Why?
|
| Intracranial Hemorrhages | 3 | 2018 | 80 | 1.210 |
Why?
|
| Blood Flow Velocity | 26 | 2021 | 172 | 1.210 |
Why?
|
| Cohort Studies | 29 | 2021 | 2356 | 1.190 |
Why?
|
| Sleep Wake Disorders | 2 | 2019 | 94 | 1.170 |
Why?
|
| Disorders of Excessive Somnolence | 2 | 2017 | 28 | 1.160 |
Why?
|
| Adult | 71 | 2022 | 21379 | 1.130 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2017 | 91 | 1.090 |
Why?
|
| Health Surveys | 8 | 2017 | 488 | 1.080 |
Why?
|
| Mass Screening | 7 | 2021 | 838 | 1.040 |
Why?
|
| Comorbidity | 12 | 2017 | 1425 | 1.040 |
Why?
|
| Fibrinolytic Agents | 9 | 2017 | 377 | 0.980 |
Why?
|
| Hospitalization | 13 | 2020 | 977 | 0.970 |
Why?
|
| Hypertension | 11 | 2022 | 1533 | 0.960 |
Why?
|
| Cross-Sectional Studies | 19 | 2020 | 2265 | 0.910 |
Why?
|
| Socioeconomic Factors | 14 | 2019 | 955 | 0.890 |
Why?
|
| Hydroxyurea | 6 | 2021 | 57 | 0.870 |
Why?
|
| Mortality | 3 | 2019 | 162 | 0.870 |
Why?
|
| Health Literacy | 2 | 2014 | 62 | 0.870 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 7 | 2022 | 29 | 0.860 |
Why?
|
| Cardiovascular Diseases | 12 | 2019 | 938 | 0.860 |
Why?
|
| Young Adult | 28 | 2022 | 5710 | 0.840 |
Why?
|
| Diabetes Mellitus | 6 | 2020 | 694 | 0.780 |
Why?
|
| Antisickling Agents | 3 | 2021 | 20 | 0.780 |
Why?
|
| Chronic Disease | 6 | 2017 | 1329 | 0.770 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2004 | 234 | 0.770 |
Why?
|
| Prevalence | 15 | 2021 | 1609 | 0.770 |
Why?
|
| Nervous System Diseases | 5 | 2020 | 142 | 0.750 |
Why?
|
| Metabolic Syndrome | 7 | 2020 | 191 | 0.750 |
Why?
|
| Snoring | 2 | 2017 | 8 | 0.740 |
Why?
|
| Aged, 80 and over | 21 | 2022 | 4843 | 0.730 |
Why?
|
| Absenteeism | 2 | 2017 | 27 | 0.730 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 3256 | 0.730 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 503 | 0.730 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 319 | 0.720 |
Why?
|
| Quality of Life | 6 | 2022 | 1515 | 0.710 |
Why?
|
| Independent Living | 2 | 2019 | 44 | 0.710 |
Why?
|
| Remote Consultation | 6 | 2014 | 50 | 0.700 |
Why?
|
| Hand Strength | 2 | 2020 | 47 | 0.700 |
Why?
|
| Cerebral Arteries | 7 | 2018 | 50 | 0.700 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 245 | 0.700 |
Why?
|
| Melatonin | 1 | 2019 | 39 | 0.690 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 207 | 0.690 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2016 | 1085 | 0.690 |
Why?
|
| Cerebral Infarction | 14 | 2006 | 103 | 0.690 |
Why?
|
| Risk Assessment | 14 | 2018 | 2004 | 0.680 |
Why?
|
| Sleep | 2 | 2022 | 263 | 0.680 |
Why?
|
| Vitamin D Deficiency | 3 | 2021 | 292 | 0.680 |
Why?
|
| Incidence | 19 | 2021 | 1582 | 0.640 |
Why?
|
| Brain | 16 | 2018 | 2176 | 0.640 |
Why?
|
| Sickle Cell Trait | 5 | 2021 | 24 | 0.630 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 186 | 0.620 |
Why?
|
| Risk | 14 | 2015 | 563 | 0.620 |
Why?
|
| Teaching Rounds | 1 | 2017 | 5 | 0.610 |
Why?
|
| Restless Legs Syndrome | 1 | 2017 | 18 | 0.610 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2016 | 766 | 0.610 |
Why?
|
| Sick Leave | 1 | 2017 | 6 | 0.600 |
Why?
|
| Sleep Aids, Pharmaceutical | 1 | 2017 | 6 | 0.600 |
Why?
|
| Education, Distance | 1 | 2017 | 34 | 0.590 |
Why?
|
| Ischemic Attack, Transient | 5 | 2010 | 167 | 0.590 |
Why?
|
| Polysomnography | 5 | 2022 | 92 | 0.590 |
Why?
|
| Age Factors | 16 | 2019 | 1860 | 0.580 |
Why?
|
| Sleep, REM | 2 | 2022 | 93 | 0.580 |
Why?
|
| Vehicle Emissions | 1 | 2016 | 11 | 0.570 |
Why?
|
| Erythrocyte Transfusion | 6 | 2022 | 72 | 0.560 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2021 | 2222 | 0.560 |
Why?
|
| Inhalation Exposure | 1 | 2016 | 33 | 0.560 |
Why?
|
| Longitudinal Studies | 11 | 2018 | 1054 | 0.550 |
Why?
|
| Disability Evaluation | 1 | 2018 | 298 | 0.540 |
Why?
|
| Air Pollutants | 1 | 2016 | 75 | 0.530 |
Why?
|
| Muscle Strength | 1 | 2016 | 62 | 0.530 |
Why?
|
| Withholding Treatment | 2 | 2014 | 35 | 0.530 |
Why?
|
| Treatment Outcome | 15 | 2022 | 7028 | 0.520 |
Why?
|
| Patient Discharge | 5 | 2022 | 294 | 0.500 |
Why?
|
| Vitamin D | 3 | 2021 | 516 | 0.500 |
Why?
|
| Upper Extremity | 3 | 2022 | 112 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 772 | 0.500 |
Why?
|
| Coronary Disease | 4 | 2021 | 358 | 0.490 |
Why?
|
| Recovery of Function | 5 | 2022 | 506 | 0.490 |
Why?
|
| Hypoxia | 1 | 2015 | 169 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2022 | 929 | 0.470 |
Why?
|
| Severity of Illness Index | 9 | 2018 | 1851 | 0.470 |
Why?
|
| Simian Immunodeficiency Virus | 3 | 2022 | 28 | 0.470 |
Why?
|
| Infant | 18 | 2021 | 2891 | 0.460 |
Why?
|
| Hemoglobins | 3 | 2018 | 120 | 0.450 |
Why?
|
| Obesity | 9 | 2016 | 1074 | 0.450 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2004 | 56 | 0.440 |
Why?
|
| Emergency Service, Hospital | 7 | 2016 | 711 | 0.440 |
Why?
|
| Depressive Disorder | 1 | 2017 | 621 | 0.440 |
Why?
|
| Magnetic Resonance Angiography | 8 | 2019 | 181 | 0.440 |
Why?
|
| Health Behavior | 4 | 2014 | 458 | 0.440 |
Why?
|
| Patients | 1 | 2012 | 69 | 0.420 |
Why?
|
| Hypercholesterolemia | 4 | 2019 | 86 | 0.410 |
Why?
|
| United States | 22 | 2022 | 7338 | 0.410 |
Why?
|
| Hand | 3 | 2022 | 90 | 0.410 |
Why?
|
| Hospitals, Rural | 5 | 2017 | 43 | 0.400 |
Why?
|
| Lung | 1 | 2016 | 849 | 0.400 |
Why?
|
| Transfusion Reaction | 4 | 2009 | 33 | 0.400 |
Why?
|
| Heart Diseases | 6 | 2016 | 276 | 0.390 |
Why?
|
| Prognosis | 10 | 2021 | 2093 | 0.380 |
Why?
|
| Health Status | 3 | 2012 | 429 | 0.380 |
Why?
|
| Primary Prevention | 4 | 2020 | 115 | 0.380 |
Why?
|
| Sex Factors | 9 | 2019 | 1265 | 0.370 |
Why?
|
| Time Factors | 12 | 2018 | 4655 | 0.370 |
Why?
|
| Iron Overload | 2 | 2009 | 28 | 0.360 |
Why?
|
| Clinical Trials as Topic | 7 | 2022 | 848 | 0.350 |
Why?
|
| American Heart Association | 4 | 2010 | 142 | 0.350 |
Why?
|
| Ferritins | 1 | 2009 | 49 | 0.340 |
Why?
|
| Cerebral Angiography | 5 | 2012 | 151 | 0.340 |
Why?
|
| Insurance Benefits | 1 | 2009 | 6 | 0.340 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 12 | 0.340 |
Why?
|
| Psychosocial Deprivation | 1 | 2009 | 1 | 0.340 |
Why?
|
| Internet | 4 | 2007 | 390 | 0.330 |
Why?
|
| Biomarkers | 8 | 2019 | 1593 | 0.330 |
Why?
|
| Research Design | 3 | 2018 | 729 | 0.330 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 82 | 0.320 |
Why?
|
| Medically Underserved Area | 2 | 2006 | 85 | 0.320 |
Why?
|
| Residence Characteristics | 4 | 2012 | 252 | 0.320 |
Why?
|
| Odds Ratio | 4 | 2015 | 880 | 0.310 |
Why?
|
| Body Mass Index | 5 | 2020 | 866 | 0.310 |
Why?
|
| Retrospective Studies | 14 | 2022 | 7268 | 0.310 |
Why?
|
| Health Education | 2 | 2009 | 279 | 0.300 |
Why?
|
| Cholesterol | 1 | 2009 | 331 | 0.300 |
Why?
|
| Managed Care Programs | 3 | 2004 | 45 | 0.300 |
Why?
|
| Myocardial Infarction | 2 | 2010 | 807 | 0.300 |
Why?
|
| Bone Marrow Transplantation | 3 | 2015 | 149 | 0.300 |
Why?
|
| Morphine | 2 | 2006 | 76 | 0.290 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2010 | 373 | 0.290 |
Why?
|
| Neuroimaging | 4 | 2021 | 122 | 0.290 |
Why?
|
| Parents | 1 | 2010 | 309 | 0.290 |
Why?
|
| South Carolina | 8 | 2018 | 2752 | 0.270 |
Why?
|
| Carotid Artery, Internal | 5 | 2006 | 85 | 0.270 |
Why?
|
| Thrombolytic Therapy | 4 | 2017 | 233 | 0.270 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 301 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 212 | 0.270 |
Why?
|
| Testosterone | 2 | 2016 | 96 | 0.270 |
Why?
|
| Surveys and Questionnaires | 8 | 2018 | 2798 | 0.260 |
Why?
|
| Transplantation Conditioning | 2 | 2015 | 34 | 0.260 |
Why?
|
| Pediatrics | 2 | 2011 | 341 | 0.260 |
Why?
|
| Multivariate Analysis | 7 | 2018 | 1046 | 0.260 |
Why?
|
| Smoking | 7 | 2014 | 1449 | 0.250 |
Why?
|
| Georgia | 6 | 2015 | 161 | 0.250 |
Why?
|
| Hemoglobin SC Disease | 2 | 2000 | 7 | 0.250 |
Why?
|
| Social Class | 4 | 2012 | 127 | 0.250 |
Why?
|
| Virus Replication | 3 | 2015 | 104 | 0.240 |
Why?
|
| Reproducibility of Results | 8 | 2015 | 2077 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 786 | 0.240 |
Why?
|
| Vertebral Artery | 2 | 1994 | 22 | 0.230 |
Why?
|
| Prospective Studies | 13 | 2021 | 3703 | 0.230 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2004 | 29 | 0.230 |
Why?
|
| Environment Design | 2 | 2014 | 40 | 0.230 |
Why?
|
| Age Distribution | 4 | 2007 | 319 | 0.230 |
Why?
|
| Endothelium, Vascular | 3 | 2018 | 371 | 0.230 |
Why?
|
| Basilar Artery | 2 | 1994 | 38 | 0.230 |
Why?
|
| Logistic Models | 7 | 2012 | 1419 | 0.230 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 791 | 0.220 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 1465 | 0.220 |
Why?
|
| Neoplasms | 2 | 2017 | 1664 | 0.210 |
Why?
|
| Cerebral Arterial Diseases | 3 | 1994 | 28 | 0.210 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2003 | 43 | 0.210 |
Why?
|
| Patient Selection | 3 | 2012 | 592 | 0.210 |
Why?
|
| Delivery of Health Care | 2 | 2005 | 445 | 0.210 |
Why?
|
| Inflammation | 3 | 2020 | 1030 | 0.210 |
Why?
|
| Analgesics, Opioid | 2 | 2006 | 498 | 0.210 |
Why?
|
| Triglycerides | 4 | 2016 | 184 | 0.210 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 16 | 0.200 |
Why?
|
| Middle Cerebral Artery | 5 | 2011 | 57 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2015 | 134 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2018 | 31 | 0.200 |
Why?
|
| Infant, Newborn | 4 | 2013 | 2455 | 0.200 |
Why?
|
| Walking | 2 | 2014 | 241 | 0.200 |
Why?
|
| Blood Glucose | 5 | 2016 | 631 | 0.190 |
Why?
|
| Emergency Medical Services | 2 | 2005 | 225 | 0.190 |
Why?
|
| Phenotype | 4 | 2020 | 946 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 2014 | 117 | 0.190 |
Why?
|
| Urban Population | 2 | 2017 | 254 | 0.190 |
Why?
|
| Body Weight | 3 | 2018 | 554 | 0.190 |
Why?
|
| Nutritional Status | 2 | 2020 | 112 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2018 | 24 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 186 | 0.190 |
Why?
|
| Arterial Occlusive Diseases | 3 | 1992 | 134 | 0.190 |
Why?
|
| Regression Analysis | 8 | 2014 | 737 | 0.180 |
Why?
|
| Disease Progression | 2 | 2016 | 1037 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2014 | 378 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2020 | 267 | 0.180 |
Why?
|
| Macaca nemestrina | 6 | 2022 | 23 | 0.180 |
Why?
|
| Cholesterol, HDL | 3 | 2016 | 112 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 105 | 0.180 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2019 | 17 | 0.180 |
Why?
|
| alpha-Thalassemia | 2 | 2003 | 7 | 0.180 |
Why?
|
| Heart Failure | 2 | 2020 | 1179 | 0.170 |
Why?
|
| Serum Amyloid A Protein | 1 | 2019 | 33 | 0.170 |
Why?
|
| Brain Infarction | 2 | 2011 | 54 | 0.170 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 497 | 0.170 |
Why?
|
| Aging | 1 | 2005 | 911 | 0.170 |
Why?
|
| Marital Status | 1 | 2019 | 65 | 0.170 |
Why?
|
| Recurrence | 5 | 2021 | 948 | 0.170 |
Why?
|
| Inflammasomes | 1 | 2019 | 39 | 0.170 |
Why?
|
| Military Personnel | 1 | 2022 | 221 | 0.170 |
Why?
|
| Cognition Disorders | 3 | 2018 | 342 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 597 | 0.170 |
Why?
|
| Urban Health | 2 | 2016 | 49 | 0.160 |
Why?
|
| Linear Models | 3 | 2016 | 521 | 0.160 |
Why?
|
| Busulfan | 1 | 2018 | 13 | 0.160 |
Why?
|
| Ultrasonography | 5 | 1997 | 453 | 0.160 |
Why?
|
| Hemoglobinopathies | 2 | 2015 | 5 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2016 | 285 | 0.160 |
Why?
|
| Microglia | 1 | 2019 | 143 | 0.160 |
Why?
|
| Apolipoprotein L1 | 1 | 2018 | 16 | 0.160 |
Why?
|
| ROC Curve | 4 | 2016 | 392 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 51 | 0.160 |
Why?
|
| Whole-Body Irradiation | 1 | 2018 | 52 | 0.160 |
Why?
|
| Frailty | 1 | 2018 | 34 | 0.160 |
Why?
|
| Body Composition | 2 | 2016 | 119 | 0.160 |
Why?
|
| Single-Blind Method | 3 | 2021 | 249 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 244 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Individuality | 1 | 1998 | 44 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 92 | 0.150 |
Why?
|
| Measles virus | 1 | 2017 | 7 | 0.150 |
Why?
|
| Measles | 1 | 2017 | 6 | 0.150 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1997 | 7 | 0.150 |
Why?
|
| Forced Expiratory Volume | 2 | 2016 | 87 | 0.150 |
Why?
|
| Dyslipidemias | 2 | 2019 | 98 | 0.150 |
Why?
|
| Goals | 1 | 2018 | 65 | 0.150 |
Why?
|
| Axons | 1 | 2018 | 139 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 696 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 951 | 0.150 |
Why?
|
| Work Performance | 1 | 2017 | 3 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 69 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 514 | 0.150 |
Why?
|
| Frontal Lobe | 1 | 2018 | 156 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 116 | 0.140 |
Why?
|
| Disabled Persons | 1 | 2018 | 94 | 0.140 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 424 | 0.140 |
Why?
|
| Steroids | 3 | 2003 | 84 | 0.140 |
Why?
|
| Vital Capacity | 1 | 2016 | 43 | 0.140 |
Why?
|
| Spirometry | 1 | 2016 | 47 | 0.140 |
Why?
|
| Neural Pathways | 1 | 2018 | 323 | 0.140 |
Why?
|
| Life Change Events | 1 | 1998 | 223 | 0.140 |
Why?
|
| Motor Vehicles | 1 | 2016 | 20 | 0.140 |
Why?
|
| Dietary Supplements | 2 | 2021 | 331 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2012 | 261 | 0.140 |
Why?
|
| Dementia | 1 | 2018 | 158 | 0.140 |
Why?
|
| Geographic Mapping | 1 | 2016 | 19 | 0.140 |
Why?
|
| HIV Infections | 2 | 2022 | 775 | 0.140 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 201 | 0.140 |
Why?
|
| Registries | 1 | 2019 | 730 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2018 | 621 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 5 | 2012 | 198 | 0.130 |
Why?
|
| Drug Substitution | 1 | 2015 | 19 | 0.130 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 10 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 349 | 0.130 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 37 | 0.130 |
Why?
|
| Aspirin | 2 | 2008 | 295 | 0.130 |
Why?
|
| Videoconferencing | 2 | 2006 | 43 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 503 | 0.130 |
Why?
|
| Carotid Stenosis | 3 | 2003 | 163 | 0.130 |
Why?
|
| Students, Medical | 1 | 2017 | 210 | 0.130 |
Why?
|
| Environmental Monitoring | 1 | 2016 | 180 | 0.130 |
Why?
|
| Ceramides | 1 | 2019 | 578 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 73 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 129 | 0.130 |
Why?
|
| Thrombin | 1 | 2015 | 117 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2015 | 123 | 0.130 |
Why?
|
| Behavior, Animal | 2 | 2011 | 470 | 0.130 |
Why?
|
| Thrombosis | 2 | 2013 | 218 | 0.130 |
Why?
|
| Hemoglobin, Sickle | 5 | 2011 | 22 | 0.120 |
Why?
|
| Acute Disease | 5 | 2007 | 658 | 0.120 |
Why?
|
| Encephalitis | 1 | 2015 | 43 | 0.120 |
Why?
|
| Cognition | 1 | 2018 | 512 | 0.120 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 125 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2016 | 186 | 0.120 |
Why?
|
| Thrombopoiesis | 1 | 2014 | 4 | 0.120 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2014 | 2 | 0.120 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2014 | 2 | 0.120 |
Why?
|
| Cerebral Revascularization | 1 | 2014 | 45 | 0.120 |
Why?
|
| Thrombopoietin | 1 | 2014 | 15 | 0.120 |
Why?
|
| Cyclohexanes | 1 | 2014 | 10 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.120 |
Why?
|
| Public Facilities | 1 | 2014 | 7 | 0.120 |
Why?
|
| Architectural Accessibility | 1 | 2014 | 8 | 0.120 |
Why?
|
| Chelation Therapy | 2 | 2022 | 17 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2014 | 15 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2013 | 627 | 0.120 |
Why?
|
| Emergency Treatment | 1 | 2014 | 52 | 0.120 |
Why?
|
| Models, Statistical | 1 | 1998 | 448 | 0.120 |
Why?
|
| Overweight | 2 | 2013 | 186 | 0.120 |
Why?
|
| Seasons | 1 | 2014 | 129 | 0.120 |
Why?
|
| Animal Diseases | 1 | 2013 | 2 | 0.120 |
Why?
|
| Callithrix | 1 | 2013 | 4 | 0.120 |
Why?
|
| Health Personnel | 2 | 2022 | 286 | 0.120 |
Why?
|
| Triazoles | 1 | 2014 | 43 | 0.120 |
Why?
|
| Religion and Medicine | 1 | 2014 | 25 | 0.120 |
Why?
|
| Ventricular Function | 1 | 2014 | 93 | 0.120 |
Why?
|
| Bone Diseases | 1 | 2013 | 20 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 48 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2007 | 272 | 0.120 |
Why?
|
| State Government | 1 | 2014 | 34 | 0.120 |
Why?
|
| Depression | 1 | 2020 | 942 | 0.110 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2015 | 111 | 0.110 |
Why?
|
| Racism | 1 | 2014 | 59 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2015 | 244 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2013 | 104 | 0.110 |
Why?
|
| beta-Thalassemia | 1 | 2013 | 17 | 0.110 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1993 | 29 | 0.110 |
Why?
|
| Rural Population | 3 | 2007 | 397 | 0.110 |
Why?
|
| Androgens | 1 | 2013 | 41 | 0.110 |
Why?
|
| Neurology | 2 | 2013 | 43 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 122 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 546 | 0.110 |
Why?
|
| Pyrophosphatases | 1 | 2013 | 6 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2014 | 238 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 22 | 0.110 |
Why?
|
| Reference Standards | 2 | 2005 | 115 | 0.110 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1993 | 15 | 0.110 |
Why?
|
| Brain Diseases | 3 | 2003 | 78 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 107 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 1993 | 97 | 0.110 |
Why?
|
| Population Growth | 1 | 2012 | 6 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 42 | 0.110 |
Why?
|
| General Practitioners | 1 | 2012 | 10 | 0.110 |
Why?
|
| Educational Status | 3 | 2009 | 273 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 396 | 0.110 |
Why?
|
| Models, Biological | 2 | 2007 | 981 | 0.110 |
Why?
|
| Environment | 1 | 2013 | 115 | 0.110 |
Why?
|
| Headache | 1 | 1993 | 68 | 0.110 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 83 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2017 | 657 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2022 | 824 | 0.100 |
Why?
|
| Acetazolamide | 1 | 1992 | 8 | 0.100 |
Why?
|
| Ultrasonography, Doppler | 2 | 2003 | 57 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 45 | 0.100 |
Why?
|
| Dystonia | 1 | 1992 | 18 | 0.100 |
Why?
|
| Animals | 12 | 2022 | 20880 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2003 | 174 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 1992 | 57 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 1992 | 40 | 0.100 |
Why?
|
| Heterozygote | 3 | 2018 | 174 | 0.100 |
Why?
|
| Self Report | 1 | 2014 | 370 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2012 | 98 | 0.100 |
Why?
|
| Bias | 1 | 2012 | 148 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2014 | 384 | 0.100 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2011 | 20 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 514 | 0.100 |
Why?
|
| Perception | 1 | 2012 | 189 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 11 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 384 | 0.100 |
Why?
|
| Blood Pressure | 3 | 2021 | 1449 | 0.100 |
Why?
|
| Secondary Prevention | 2 | 2014 | 291 | 0.100 |
Why?
|
| Viral Load | 3 | 2017 | 127 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 335 | 0.100 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 124 | 0.100 |
Why?
|
| Polyradiculoneuropathy | 1 | 1990 | 3 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 648 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 1753 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2011 | 144 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 1993 | 150 | 0.090 |
Why?
|
| Health Care Surveys | 3 | 2014 | 239 | 0.090 |
Why?
|
| Administration, Inhalation | 2 | 2001 | 187 | 0.090 |
Why?
|
| Waist Circumference | 3 | 2016 | 32 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2006 | 403 | 0.090 |
Why?
|
| Jamaica | 2 | 2021 | 10 | 0.090 |
Why?
|
| Communication | 1 | 2012 | 329 | 0.090 |
Why?
|
| Respiration, Artificial | 2 | 2007 | 190 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 467 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2012 | 238 | 0.090 |
Why?
|
| Siderophores | 1 | 2009 | 16 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2014 | 738 | 0.090 |
Why?
|
| Deferoxamine | 1 | 2009 | 45 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 186 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 88 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 442 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 137 | 0.080 |
Why?
|
| Eligibility Determination | 1 | 2009 | 31 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2011 | 328 | 0.080 |
Why?
|
| Health Services | 1 | 2009 | 87 | 0.080 |
Why?
|
| Angina Pectoris | 1 | 2009 | 61 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 92 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2011 | 586 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2013 | 617 | 0.080 |
Why?
|
| Hospitals, Community | 2 | 2005 | 64 | 0.080 |
Why?
|
| Dipyridamole | 1 | 2008 | 26 | 0.080 |
Why?
|
| Liver | 2 | 2014 | 1118 | 0.080 |
Why?
|
| Length of Stay | 2 | 2009 | 780 | 0.080 |
Why?
|
| Microcirculation | 2 | 2001 | 77 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2006 | 392 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 90 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2008 | 118 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 1 | 1987 | 28 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2008 | 304 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2009 | 344 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 1987 | 107 | 0.070 |
Why?
|
| Alcohol Drinking | 3 | 2013 | 805 | 0.070 |
Why?
|
| Morphine Dependence | 1 | 2006 | 4 | 0.070 |
Why?
|
| Anterior Cerebral Artery | 1 | 2006 | 5 | 0.070 |
Why?
|
| Brazil | 1 | 2006 | 48 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 2550 | 0.070 |
Why?
|
| Cytokines | 3 | 2017 | 866 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2006 | 67 | 0.070 |
Why?
|
| Anthropometry | 1 | 2006 | 64 | 0.070 |
Why?
|
| Body Height | 1 | 2006 | 67 | 0.070 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2006 | 33 | 0.070 |
Why?
|
| Bilirubin | 1 | 2006 | 51 | 0.070 |
Why?
|
| Hospital Units | 1 | 2006 | 21 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2018 | 714 | 0.070 |
Why?
|
| Cocaine | 1 | 2011 | 555 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2017 | 76 | 0.070 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 14 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 242 | 0.070 |
Why?
|
| White Matter | 2 | 2018 | 174 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 1055 | 0.070 |
Why?
|
| Rehabilitation Centers | 1 | 2006 | 46 | 0.070 |
Why?
|
| Fasting | 1 | 2005 | 75 | 0.070 |
Why?
|
| Research Subjects | 1 | 2006 | 45 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2015 | 30 | 0.060 |
Why?
|
| Cognitive Dysfunction | 2 | 2018 | 176 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1040 | 0.060 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 517 | 0.060 |
Why?
|
| Electroencephalography | 3 | 2022 | 418 | 0.060 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2015 | 24 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 1140 | 0.060 |
Why?
|
| Health Planning Guidelines | 1 | 2005 | 23 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2015 | 92 | 0.060 |
Why?
|
| Ethics, Professional | 1 | 2004 | 8 | 0.060 |
Why?
|
| Graft vs Host Disease | 2 | 2018 | 163 | 0.060 |
Why?
|
| Down Syndrome | 2 | 1997 | 120 | 0.060 |
Why?
|
| Ischemia | 1 | 2006 | 229 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2006 | 210 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2015 | 230 | 0.060 |
Why?
|
| Constriction, Pathologic | 2 | 2015 | 236 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1990 | 756 | 0.060 |
Why?
|
| Health Policy | 1 | 2006 | 221 | 0.060 |
Why?
|
| Self Care | 1 | 2006 | 252 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 244 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2005 | 652 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2006 | 435 | 0.050 |
Why?
|
| Office Visits | 1 | 2003 | 83 | 0.050 |
Why?
|
| Moyamoya Disease | 1 | 2022 | 7 | 0.050 |
Why?
|
| Orthopedics | 1 | 2004 | 88 | 0.050 |
Why?
|
| P-Selectin | 1 | 2022 | 16 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 266 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 1997 | 2324 | 0.050 |
Why?
|
| Housing | 1 | 2022 | 38 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2004 | 135 | 0.050 |
Why?
|
| Histamine H1 Antagonists | 1 | 2002 | 22 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 55 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 219 | 0.050 |
Why?
|
| Life Tables | 1 | 2001 | 29 | 0.050 |
Why?
|
| Self Administration | 1 | 2004 | 419 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2002 | 88 | 0.050 |
Why?
|
| Motor Activity | 3 | 2013 | 621 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2003 | 230 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1174 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 58 | 0.050 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2001 | 8 | 0.050 |
Why?
|
| Minority Groups | 1 | 2003 | 196 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2022 | 156 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 214 | 0.050 |
Why?
|
| Conjunctiva | 1 | 2001 | 16 | 0.050 |
Why?
|
| Cromolyn Sodium | 1 | 2001 | 1 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2001 | 137 | 0.050 |
Why?
|
| Microscopy | 1 | 2001 | 64 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 581 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 114 | 0.050 |
Why?
|
| New Zealand | 1 | 2020 | 28 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1663 | 0.050 |
Why?
|
| Chest Pain | 1 | 2001 | 151 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2006 | 866 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2001 | 119 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2000 | 32 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 1213 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2003 | 322 | 0.050 |
Why?
|
| Exercise | 2 | 2022 | 658 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2022 | 183 | 0.040 |
Why?
|
| Employment | 2 | 2012 | 154 | 0.040 |
Why?
|
| Contrast Sensitivity | 2 | 1997 | 28 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 39 | 0.040 |
Why?
|
| Heart Rate | 1 | 2022 | 568 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 59 | 0.040 |
Why?
|
| Vidarabine | 1 | 2018 | 12 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 365 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 381 | 0.040 |
Why?
|
| Pregnatrienes | 1 | 1998 | 3 | 0.040 |
Why?
|
| Hospitals | 2 | 2015 | 265 | 0.040 |
Why?
|
| Taiwan | 1 | 1998 | 20 | 0.040 |
Why?
|
| Pain | 1 | 2001 | 472 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 107 | 0.040 |
Why?
|
| Virus Shedding | 1 | 2017 | 1 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 3 | 0.040 |
Why?
|
| Viremia | 1 | 2017 | 13 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Sample Size | 1 | 1998 | 79 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2019 | 209 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1341 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 438 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 94 | 0.040 |
Why?
|
| Connectome | 1 | 2018 | 91 | 0.040 |
Why?
|
| Brain Death | 1 | 1997 | 34 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2017 | 93 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 1998 | 201 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1997 | 164 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 1998 | 172 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 315 | 0.040 |
Why?
|
| Visual Acuity | 2 | 1997 | 236 | 0.040 |
Why?
|
| Vascular Calcification | 1 | 2018 | 131 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2017 | 86 | 0.040 |
Why?
|
| Paris | 1 | 2016 | 3 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 239 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 161 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2003 | 1549 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 226 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 122 | 0.030 |
Why?
|
| Ganglia, Spinal | 1 | 2015 | 29 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 219 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2015 | 47 | 0.030 |
Why?
|
| Nitrous Oxide | 1 | 1995 | 7 | 0.030 |
Why?
|
| Siblings | 1 | 2015 | 34 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2015 | 50 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2015 | 77 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 465 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 82 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 424 | 0.030 |
Why?
|
| Reference Values | 1 | 1996 | 579 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1692 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 1998 | 317 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 38 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 770 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 1994 | 15 | 0.030 |
Why?
|
| Syndrome | 2 | 2013 | 255 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 89 | 0.030 |
Why?
|
| Anticoagulants | 2 | 2010 | 356 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 114 | 0.030 |
Why?
|
| Indians, North American | 1 | 2014 | 64 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1994 | 63 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 101 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 2014 | 18 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Restaurants | 1 | 2014 | 29 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 85 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2016 | 241 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 102 | 0.030 |
Why?
|
| Sense of Coherence | 1 | 2014 | 1 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2014 | 8 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 43 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 100 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 55 | 0.030 |
Why?
|
| Awareness | 1 | 2014 | 81 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 87 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2014 | 34 | 0.030 |
Why?
|
| Homozygote | 1 | 1994 | 119 | 0.030 |
Why?
|
| Lymphoma | 1 | 2014 | 116 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2014 | 82 | 0.030 |
Why?
|
| Arteries | 1 | 1994 | 108 | 0.030 |
Why?
|
| Spatial Analysis | 1 | 2014 | 33 | 0.030 |
Why?
|
| Leukemia | 1 | 2014 | 117 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2015 | 195 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 53 | 0.030 |
Why?
|
| Telephone | 1 | 2014 | 160 | 0.030 |
Why?
|
| Cerebellum | 1 | 1994 | 103 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2014 | 46 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1993 | 15 | 0.030 |
Why?
|
| Diastole | 1 | 2014 | 161 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 1993 | 34 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2006 | 285 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 113 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 1993 | 481 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 237 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 1752 | 0.030 |
Why?
|
| Exome | 1 | 2013 | 20 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 117 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1994 | 235 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 2791 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 317 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 211 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 25 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 447 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 451 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 572 | 0.030 |
Why?
|
| Perfusion | 1 | 2012 | 131 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2011 | 1738 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 626 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 647 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 240 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 498 | 0.020 |
Why?
|
| beta-Globins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Macaca | 1 | 2011 | 24 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2011 | 10 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2011 | 10 | 0.020 |
Why?
|
| Cardiolipins | 1 | 1991 | 12 | 0.020 |
Why?
|
| Sensation | 1 | 1991 | 49 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 98 | 0.020 |
Why?
|
| Neural Conduction | 1 | 1990 | 24 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 1990 | 18 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2010 | 15 | 0.020 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 21 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 700 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2010 | 34 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2010 | 21 | 0.020 |
Why?
|
| Embolism | 1 | 2010 | 45 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 329 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 442 | 0.020 |
Why?
|
| Ultrasonics | 1 | 1990 | 17 | 0.020 |
Why?
|
| Antibodies | 1 | 1991 | 241 | 0.020 |
Why?
|
| Rheology | 1 | 1990 | 25 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1991 | 240 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2011 | 152 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 84 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 168 | 0.020 |
Why?
|
| Methysergide | 1 | 1989 | 4 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 1989 | 30 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 333 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 249 | 0.020 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 1988 | 1 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 281 | 0.020 |
Why?
|
| Basal Ganglia Diseases | 1 | 1988 | 13 | 0.020 |
Why?
|
| Receptors, Serotonin | 1 | 1989 | 74 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1989 | 137 | 0.020 |
Why?
|
| Mental Recall | 1 | 1989 | 72 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 1988 | 16 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 1989 | 161 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2010 | 204 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 366 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2673 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 365 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 8474 | 0.020 |
Why?
|
| Reaction Time | 2 | 2003 | 170 | 0.020 |
Why?
|
| Memory | 1 | 1989 | 214 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 94 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 126 | 0.020 |
Why?
|
| Amnesia | 1 | 1985 | 17 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2008 | 383 | 0.020 |
Why?
|
| Neutrophils | 1 | 2006 | 204 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1986 | 346 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2006 | 489 | 0.020 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2005 | 11 | 0.020 |
Why?
|
| Codes of Ethics | 1 | 2004 | 11 | 0.020 |
Why?
|
| Data Collection | 1 | 2006 | 420 | 0.020 |
Why?
|
| Marketing of Health Services | 1 | 2004 | 18 | 0.020 |
Why?
|
| Human Experimentation | 1 | 2004 | 19 | 0.020 |
Why?
|
| Meningeal Neoplasms | 1 | 1985 | 42 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 2334 | 0.020 |
Why?
|
| Professional Practice | 1 | 2004 | 47 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 2689 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2004 | 47 | 0.020 |
Why?
|
| Meningioma | 1 | 1985 | 54 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2004 | 58 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2004 | 48 | 0.020 |
Why?
|
| Utilization Review | 1 | 2004 | 48 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2004 | 48 | 0.010 |
Why?
|
| California | 1 | 2004 | 99 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 2004 | 86 | 0.010 |
Why?
|
| Research Personnel | 1 | 2004 | 83 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 188 | 0.010 |
Why?
|
| Genome, Human | 1 | 2003 | 62 | 0.010 |
Why?
|
| Cardiology | 1 | 2004 | 140 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 121 | 0.010 |
Why?
|
| Health Services Research | 1 | 2004 | 209 | 0.010 |
Why?
|
| Albinism | 1 | 1982 | 3 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2003 | 159 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 442 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1982 | 45 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 213 | 0.010 |
Why?
|
| Eye Diseases | 1 | 1982 | 38 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2001 | 35 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2001 | 43 | 0.010 |
Why?
|
| Physicians | 1 | 2005 | 324 | 0.010 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2000 | 6 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 597 | 0.010 |
Why?
|
| Emergencies | 1 | 2000 | 107 | 0.010 |
Why?
|
| History, 20th Century | 2 | 1991 | 248 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2001 | 402 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1195 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2001 | 434 | 0.010 |
Why?
|
| Vision Disorders | 2 | 1994 | 94 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1998 | 49 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 1998 | 65 | 0.010 |
Why?
|
| Placebos | 1 | 1998 | 195 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2001 | 689 | 0.010 |
Why?
|
| Pneumonia | 1 | 1998 | 110 | 0.010 |
Why?
|
| Pattern Recognition, Visual | 1 | 1997 | 69 | 0.010 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1995 | 17 | 0.010 |
Why?
|
| Eyeglasses | 1 | 1994 | 11 | 0.010 |
Why?
|
| Vision Tests | 1 | 1994 | 18 | 0.010 |
Why?
|
| Anesthesia | 1 | 1995 | 120 | 0.010 |
Why?
|
| Child Development | 1 | 1994 | 102 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 1991 | 57 | 0.010 |
Why?
|
| History, 19th Century | 1 | 1991 | 95 | 0.010 |
Why?
|
| Europe | 1 | 1991 | 196 | 0.010 |
Why?
|
| Serial Learning | 1 | 1989 | 4 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1989 | 61 | 0.010 |
Why?
|
| Pellagra | 1 | 1988 | 1 | 0.010 |
Why?
|
| Niacin | 1 | 1988 | 12 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 1989 | 79 | 0.010 |
Why?
|
| Attention | 1 | 1989 | 225 | 0.000 |
Why?
|
| Infarction | 1 | 1986 | 17 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1986 | 110 | 0.000 |
Why?
|
| Amnesia, Retrograde | 1 | 1985 | 2 | 0.000 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1985 | 138 | 0.000 |
Why?
|
| Puerto Rico | 1 | 1982 | 24 | 0.000 |
Why?
|
| Nystagmus, Pathologic | 1 | 1982 | 12 | 0.000 |
Why?
|